Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 4 | 1 |
List of Figures | 4 | 1 |
Introduction | 5 | 1 |
Global Markets Direct Report Coverage | 5 | 1 |
Vaginal Atrophy (Atrophic Vaginitis) Overview | 6 | 1 |
Therapeutics Development | 7 | 1 |
Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) Overview | 7 | 1 |
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics under Development by Companies | 8 | 1 |
Vaginal Atrophy (Atrophic Vaginitis) Pipeline Products Glance | 9 | 3 |
Late Stage Products | 9 | 1 |
Clinical Stage Products | 10 | 1 |
Early Stage Products | 11 | 1 |
Vaginal Atrophy (Atrophic Vaginitis) Products under Development by Companies | 12 | 1 |
Vaginal Atrophy (Atrophic Vaginitis) Companies Involved in Therapeutics Development | 13 | 6 |
Allergan Plc | 13 | 1 |
EndoCeutics, Inc. | 14 | 1 |
Foamix Pharmaceuticals Ltd. | 15 | 1 |
Ligand Pharmaceuticals, Inc. | 16 | 1 |
Mithra Pharmaceuticals S.A. | 17 | 1 |
PEPTONIC medical AB | 18 | 1 |
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics Assessment | 19 | 9 |
Assessment by Monotherapy Products | 19 | 1 |
Assessment by Target | 20 | 2 |
Assessment by Mechanism of Action | 22 | 2 |
Assessment by Route of Administration | 24 | 2 |
Assessment by Molecule Type | 26 | 2 |
Drug Profiles | 28 | 13 |
Estetrol Drug Profile | 28 | 3 |
estradiol hemihydrate Drug Profile | 31 | 1 |
lasofoxifene tartrate Drug Profile | 32 | 3 |
oxytocin Drug Profile | 35 | 2 |
prasterone Drug Profile | 37 | 2 |
WC-3011 Drug Profile | 39 | 2 |
Vaginal Atrophy (Atrophic Vaginitis) Dormant Projects | 41 | 1 |
Vaginal Atrophy (Atrophic Vaginitis) Product Development Milestones | 42 | 9 |
Featured News &Press Releases | 42 | 1 |
May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor | 42 | 1 |
Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study | 42 | 1 |
Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting | 43 | 1 |
Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause | 44 | 1 |
Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting | 45 | 1 |
Jul 17, 2015: Last subject exits Peptonic Medical s phase 2b VVA study | 46 | 1 |
Mar 30, 2015: Vulvovaginal atrophy symptoms improve with prasterone treatment | 46 | 1 |
Mar 23, 2015: Peptonic Medical s formulation patent to be approved in the USA | 47 | 1 |
Mar 18, 2015: Patient recruitment to Peptonic Medical s phase 2b study soon completed | 47 | 1 |
Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin | 48 | 1 |
Dec 01, 2014: Peptonic Medical s formulation patent to be approved in Europe | 48 | 1 |
Oct 28, 2014: First patients included in Peptonic Medical AB s clinical phase 2b study | 48 | 1 |
Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study | 49 | 1 |
Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study | 49 | 1 |
Mar 01, 2013: Peptonic Medical Receives New Formulation Patent For Vagitocin In Sweden | 50 | 1 |
Appendix | 51 | 2 |
Methodology | 51 | 1 |
Coverage | 51 | 1 |
Secondary Research | 51 | 1 |
Primary Research | 51 | 1 |
Expert Panel Validation | 51 | 1 |
Contact Us | 51 | 1 |
Disclaimer | 52 | 1 |